×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CDTX – cidara therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CDTX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/11
11:15 pm
cdtx
Cidara Therapeutics, Inc. (NASDAQ: CDTX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Cidara Therapeutics, Inc. (NASDAQ: CDTX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/11
11:15 pm
cdtx
Cidara Therapeutics, Inc. (NASDAQ: CDTX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Cidara Therapeutics, Inc. (NASDAQ: CDTX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/11
08:09 am
cdtx
Cidara Therapeutics, Inc. (NASDAQ: CDTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $24.00 price target on the stock.
Low
Report
Cidara Therapeutics, Inc. (NASDAQ: CDTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $24.00 price target on the stock.
11/7
06:21 pm
cdtx
Cidara Therapeutics GAAP EPS of -$2.38 beats by $1.87 [Seeking Alpha]
Medium
Report
Cidara Therapeutics GAAP EPS of -$2.38 beats by $1.87 [Seeking Alpha]
11/7
04:15 pm
cdtx
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Low
Report
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
10/31
08:00 am
cdtx
Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences
Low
Report
Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences
10/22
08:32 am
cdtx
Cidara Therapeutics, Inc. (NASDAQ: CDTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $24.00 price target on the stock.
Low
Report
Cidara Therapeutics, Inc. (NASDAQ: CDTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $24.00 price target on the stock.
10/16
08:00 am
cdtx
Cidara Therapeutics Announces Two Presentations on Drug-Fc Conjugate, CD388, at IDWeek 2024
Medium
Report
Cidara Therapeutics Announces Two Presentations on Drug-Fc Conjugate, CD388, at IDWeek 2024
Date
Time
Symbol
Company Name
Action
%Chg
5/15/2024
04:09 pm
CDTX
cidara therapeutics, inc.
MISS
Report
-6.4%
cidara therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/7
04:22 pm
cdtx
Form 8-K Cidara Therapeutics, For: Nov 07
Low
Report
Form 8-K Cidara Therapeutics, For: Nov 07
11/7
04:11 pm
cdtx
Form 10-Q Cidara Therapeutics, For: Sep 30
Low
Report
Form 10-Q Cidara Therapeutics, For: Sep 30
10/2
05:30 pm
cdtx
Form 4 Cidara Therapeutics, For: Sep 30 Filed by: Sandison Taylor
Low
Report
Form 4 Cidara Therapeutics, For: Sep 30 Filed by: Sandison Taylor
10/2
05:28 pm
cdtx
Form 4 Cidara Therapeutics, For: Sep 30 Filed by: Tari Leslie
Low
Report
Form 4 Cidara Therapeutics, For: Sep 30 Filed by: Tari Leslie
10/2
05:25 pm
cdtx
Form 4 Cidara Therapeutics, For: Sep 30 Filed by: Stein Jeffrey
Low
Report
Form 4 Cidara Therapeutics, For: Sep 30 Filed by: Stein Jeffrey
10/2
05:19 pm
cdtx
Form 4 Cidara Therapeutics, For: Sep 30 Filed by: Shah Preetam
Low
Report
Form 4 Cidara Therapeutics, For: Sep 30 Filed by: Shah Preetam
10/2
05:18 pm
cdtx
Form 4 Cidara Therapeutics, For: Sep 30 Filed by: Ward Shane
Low
Report
Form 4 Cidara Therapeutics, For: Sep 30 Filed by: Ward Shane
9/23
08:10 am
cdtx
Form 8-K Cidara Therapeutics, For: Sep 23
Medium
Report
Form 8-K Cidara Therapeutics, For: Sep 23
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
9/3
Cidara Therapeutics and Mundipharma Form Strategic Partnership to Develop and Commercialize Rezafungin
39.9%
1/22 Form 424B5 Cidara Therapeutics, 17.9%
12/26 Cidara Therapeutics Inc (NASDAQ: CDTX) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 10.5%
3/4 Q4/2019 12/31/2019 EPS -0.420 ZacksConsensus -0.280 ActVsEst (0.140) - Miss 10.1%
1/14 Cidara Therapeutics Inc (NASDAQ: CDTX) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.4%
6/5 Cidara Therapeutics Inc (NASDAQ: CDTX) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $6.00 price target on the stock. 8.4%
3/23 Form 4 Cidara Therapeutics, For: Mar 19 Filed by: Sandison Taylor 7.7%
6/27 Form 4 Cidara Therapeutics, For: Jun 17 Filed by: Mineo Chrysa 7.0%
8/7 Cidara Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference 6.4%
1/6 Form 4 Cidara Therapeutics, For: Jan 03 Filed by: Daruwala Paul 6.4%
1/22 Form 424B5 Cidara Therapeutics, 17.9%
12/26 Cidara Therapeutics Inc (NASDAQ: CDTX) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 10.5%
3/4 Q4/2019 12/31/2019 EPS -0.420 ZacksConsensus -0.280 ActVsEst (0.140) - Miss 10.1%
1/14 Cidara Therapeutics Inc (NASDAQ: CDTX) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.4%
6/5 Cidara Therapeutics Inc (NASDAQ: CDTX) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $6.00 price target on the stock. 8.4%
3/23 Form 4 Cidara Therapeutics, For: Mar 19 Filed by: Sandison Taylor 7.7%
6/27 Form 4 Cidara Therapeutics, For: Jun 17 Filed by: Mineo Chrysa 7.0%
8/7 Cidara Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference 6.4%
1/6 Form 4 Cidara Therapeutics, For: Jan 03 Filed by: Daruwala Paul 6.4%
TOP News Decliners
9/3
Thinking about buying stock in Cidara Therapeutics, Canopy Growth, Generac, Lowe's, or Medicines Co?
-22.6%
7/29 Form 8-K Cidara Therapeutics, For: Jul 29 -14.7%
9/3 Cidara Therapeutics Inc (NASDAQ: CDTX) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating. -13.5%
1/13 Form 8-K Cidara Therapeutics, For: Jan 13 -10.8%
4/7 Cidara Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference -7.8%
2/21 Form SC 13G Cidara Therapeutics, Filed by: Stonepine Capital Management, LLC -7.4%
1/10 Cidara Therapeutics Announces Proposed Rights Offering -6.7%
7/29 Form 8-K Cidara Therapeutics, For: Jul 29 -6.1%
4/28 Cidara Therapeutics to Participate in Antifungal and COVID-19 Therapeutics Panels at Maxim Group’s Infectious Disease Virtual Conference -6.0%
10/1 Form 4 Cidara Therapeutics, For: Sep 27 Filed by: Oien Jessica -5.9%
7/29 Form 8-K Cidara Therapeutics, For: Jul 29 -14.7%
9/3 Cidara Therapeutics Inc (NASDAQ: CDTX) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating. -13.5%
1/13 Form 8-K Cidara Therapeutics, For: Jan 13 -10.8%
4/7 Cidara Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference -7.8%
2/21 Form SC 13G Cidara Therapeutics, Filed by: Stonepine Capital Management, LLC -7.4%
1/10 Cidara Therapeutics Announces Proposed Rights Offering -6.7%
7/29 Form 8-K Cidara Therapeutics, For: Jul 29 -6.1%
4/28 Cidara Therapeutics to Participate in Antifungal and COVID-19 Therapeutics Panels at Maxim Group’s Infectious Disease Virtual Conference -6.0%
10/1 Form 4 Cidara Therapeutics, For: Sep 27 Filed by: Oien Jessica -5.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: